Preview

PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology

Advanced search

PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION

Abstract

Comparative pharmacoeconomic analysis of two therapeutic strategy (the strategy A and the strategy B), which differ with the expansion of access to ART was conducted using deterministic model. The aim of this research was to optimize the therapy of HIV-infected people and determine the most effective therapeutic strategy. On the basis of obtained epidemiological data model determines the advantages of therapeutic strategy with higher access to ART (strategy B). In particular, the results of simulation showed that the application of ART allows to significantly reduce new HIV infections and deaths related to the virus. Use of ART allows to optimize the costs, the value of quality-adjusted life year (QALY) is growing, which makes it advisable to use ART in health care on larger scale.

About the Authors

V. A. Chibilyaev
The First MSMU named after I.M. Sechenov
Russian Federation
Laboratory of pharmacoeconomical research


A. Yu. Kulikov
The First MSMU named after I.M. Sechenov
Russian Federation

Laboratory of pharmacoeconomical research



R. I. Yagudina
The First MSMU named after I.M. Sechenov
Russian Federation
Laboratory of pharmacoeconomical research


References

1. Бергер М.Л., Бингерфорс К., Хедблом Э.С., Пашос К.Л. Книга терминов ISPOR – Затраты, качество и результаты в здравоохранении. 2009.

2. Плавинский С.Л. Моделирование ВИЧ-инфекции и других заразных заболеваний человека и оценка численности групп риска. Введение в математическую эпидемиологию. М. 2009; 100 с.

3. Покровский В.В., Юрин О.Г., Беляева В.В., Буравцова Е.В., Аляева М.Д. Методические указания «Диспансерное наблюдение за пациентами с ВИЧ-инфекцией». 2006.

4. Ющук Н.Д., Венгеров Ю.Я., Шахгильдян И.В., Нагибина М.В., Ченцов В.Б., Груздев Б.М., Баринова А.А., Мартынова Н.Н., Мясников В.А. Интенсивная и паллиативная терапия больных ВИЧ- инфекцией. Лечащий врач. 2008; 9.

5. Ягудина Р.И., Куликов А.Ю., Зинчук И.Ю. Фармакоэкономическое моделирование применения лекарственных средств прилечении ВИЧ-инфекции. Фармакокономика. 2011; 2.

6. Barcal K., Schumacher J., Dumchev K., Moroz L. A situational picture of HIV/AIDS and injection drug use in Vinnitsya, Ukraine. Harm Reduct J. 2005; 2: 16.

7. Booth R.E., Kwiatkowski C.F., Brewster J.T., Sinitsyna L., Dvoryak S. Predictors of HIV sero-status among drug injectors at three Ukraine sites. AIDS. 2006; 20: 2217-2223.

8. Booth R.E., Kwiatkowski C.F., Mikulich-Gilbertson S.K., Brewster J.T., Salomonsen-Sautel S. et al. Predictors of risky needle use following interventions with injection drug users in Ukraine. Drug. Alcohol. Depend. 2006; 82: 49-55.

9. Booth R.E., Mikulich-Gilbertson S.K., Brewster J.T., Salomonsen-Sautel S., Semerik O. Predictors of Self-Reported HIV Infection Among Drug Injectors in Ukraine. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2004; 35: 82-88.

10. Bruce R.D., Dvoryak S., Sylla L., Altice F.L. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine--programme description and policy implications. Int. J. Drug. Policy. 2007; 18: 326-328.

11. Castilla J., del Romero J., Hernando V., Marincovich B., Garcia S. et al. Effectiveness of highly active antiretroviral therapy in reducing heterosexual transmission of HIV. J. AIDS. 2005; 40: 96-101.

12. Dvoriak S. Opioid Substitution Therapy (OST) with Buprenorphine in Ukraine – Way to Prevent HIV/AIDS among IDUs.2007; Sydney, Australia.

13. Feshbach M., Galvin C. HIV/AIDS in Ukraine – An Analysis of Statistics. Washington, DC: Woodrow Wilson International Center for Scholars. 2005.

14. Grönbladh L., Öhlund L.S., Gunne L.M. Mortality in heroin addiction: impact of methadone treatment. Acta Psychiatr. Scand. 1990; 82: 223-227.

15. http://www.who.int/mediacentre/news/releases/2009/hiv_aids_20091124/ru/index.html. Сайт ВОЗ.

16. http://www.who.int/features/qa/71/ru/index.html. Сайт ВОЗ.

17. http://www.hivrussia.net/stat/index.shtml. Федеральный научно-методический Центр по профилактике и борьбе со СПИДом.

18. http://www.who.int/hiv/topics/treatment/art/ru/index html. Сайт ВОЗ.

19. http://www.aidsinfonet.org/fact_sheets/view/403?lang=eng

20. Joint United Nations Programme on HIV/AIDS (UNAIDS) Ukraine – National report on monitoring progress towards the UNGASS declaration of commitment on HIV/AIDS. Geneva: United Nations. 2008.

21. Kousignian I., Abgrall S., Grabar S., Mahamat A., Teicher E., Rouveix E., Costagliola D. and the Clinical Epidemiology Group of the French Hospital Database on HIV .Maintaining Antiretroviral Therapy Reduces the Risk of AIDS-Defining Events in Patients with – Uncontrolled Viral Replication and ProfoundImmunodeficiency. Oxford Journals. 2008; 2.

22. Kruglov Y.V., Kobyshcha Y.V., Salyuk T., Varetska O., Shakarishvili A. et al. The most severe HIV epidemic in Europe: Ukraine's national HIV prevalence estimates for 2007. Sex Transm. Infect. 2008; 84: i37-41.

23. Long E.F., Brandeau M.L., Galvin C.M., Vinichenko T., Tole S.P. et al. Effectiveness and cost-effectiveness of strategies to expand antiretroviral therapy in St. Petersburg, Russia. AIDS. 2006; 20: 2207- 2215.

24. Panel on Antiretroviral Guidelines for Adults and Adolescents Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Bethesda, MD: United States Department of Health and Human Services. 2008.

25. Pinkerton S.D., Abramson P.R. Effectiveness of condoms in preventing HIV transmission. Soc. Sci Med. 1997; 44: 1303-1312.

26. Sabina S. Alistar, Douglas K. Owens, Margaret L. Brandeau et al. Effectiveness and Cost Effectiveness of Expanding Harm Reduction and Antiretroviral Therapy in a Mixed HIV Epidemic: A Modeling Analysis for Ukraine. 2011.

27. Sanders G.D., Bayoumi A.M., Sundaram V., Bilir S.P., Neukermans C.P. et al. Cost-effectiveness of screening for HIV in the era of highly active antiretroviral therapy. N. Engl. J. Med. 2005; 352: 570-585.

28. Smyrnov P. Making the change: 3 years of Global Fund supported treatment in Ukraine – Evidence versus policy. Tbilisi, Georgia: International HIV/AIDS Alliance in Ukraine. 2007.

29. Tengs T.O., Lin T.H. A meta-analysis of utility estimates for HIV/ AIDS. Med. Decis. Making. 2002; 22: 475-481.

30. The World Bank Socioeconomic Impact of HIV/AIDS in Ukraine. Washington, DC: World Bank. 2006.

31. Vickerman P., Kumaranayake L., Balakireva O., Guinness L., Artyukh O. et al. The cost-effectiveness of expanding harm reduction activities for injecting drug users in Odessa, Ukraine. Sex Transm. Dis. 2006; 33: 89-102.

32. World Health Organization (WHO) Antiretroviral Therapy for HIV Infection in Adults and adolescents: Recommendations for a Public Health Approach – 2006 Revision. Geneva: World Health Organization. 2006

33. World Health Organization (WHO) Summary Country Profile for HIV/AIDS Treatment Scale-Up – Ukraine. Geneva: World Health Organization. 2005.

34. Zaric G., Barnett P., Brandeau M. HIV transmission and the costeffectiveness of methadone maintenance. Am. J. Public. Health. 2000; 90: 1100-1111.

35. Zaric G.S., Brandeau M.L., Barnett P.G. Methadone maintenance and HIV prevention: cost-effectiveness analysis. Manage Sci. 2000; 46: 1013-1031.


For citation:


Chibilyaev V.A., Kulikov A.Y., Yagudina R.I. PHARMACOECONOMIC MODELING OF ANTIRETROVIRAL DRUGS USE DURING TREATMENT OF HIV INFECTION. PHARMACOECONOMICS. Modern pharmacoeconomics and pharmacoepidemiology. 2013;6(2):21-32.

Views: 285


ISSN 2070-4909 (Print)
ISSN 2070-4933 (Online)